Explore the vast range of titles available.

Presents several experiments with sound.

Presents several experiments with plants and discusses biology.

Faunal assemblages from the pre-Contact period sites Frisby-Butler and Hornblower II on Marthaʼs Vineyard, Massachusetts, USA, remain unstudied since excavation during the 1980s. This project establishes radiocarbon (14C) dates from faunal remains and evaluates occupation and abandonment at each site. 14C measurements were collected from 17 specimens and 13 dates from previous analyses were re-examined. Dates were identified from the archaeological time periods Transitional Archaic (2700–3700 BP), Early Woodland (2000–2700 BP), and Late Woodland (450–1200 BP) at Frisby-Butler. Occupation likely represented seasonal visitations during autumn and winter to hunt based on white-tailed deer (Odocoileus virginianus) demographic profiles. A combined dataset of new and re-calibrated 14C measurements from Hornblower II date to the Late Archaic (3700–6000 BP), Early Woodland, Middle Woodland (1200–2000 BP), and Late Woodland periods. Settlement was focused on gathering warm-weather foods like demersal fish and lakebirds. Together, the sites demonstrate periodic seasonal use of the southwest coast of the island throughout the Late Holocene and fit within an established regional pattern in southern New England.

Presents several mysterious science experiments.

The prevalence of coeliac disease (CD) is around 1%, but diagnosis is challenged by varied presentation and non-specific symptoms and signs. This study aimed to identify diagnostic indicators that may help identify patients at a higher risk of CD in whom further testing is warranted. International guidance for systematic review methods were followed and the review was registered at PROSPERO (CRD42020170766). Six databases were searched until April 2021. Studies investigating diagnostic indicators, such as symptoms or risk conditions, in people with and without CD were eligible for inclusion. Risk of bias was assessed using the QUADAS-2 tool. Summary sensitivity, specificity, and positive predictive values were estimated for each diagnostic indicator by fitting bivariate random effects meta-analyses. 191 studies reporting on 26 diagnostic indicators were included in the meta-analyses. We found large variation in diagnostic accuracy estimates between studies and most studies were at high risk of bias. We found strong evidence that people with dermatitis herpetiformis, migraine, family history of CD, HLA DQ2/8 risk genotype, anaemia, type 1 diabetes, osteoporosis, or chronic liver disease are more likely than the general population to have CD. Symptoms, psoriasis, epilepsy, inflammatory bowel disease, systemic lupus erythematosus, fractures, type 2 diabetes, and multiple sclerosis showed poor diagnostic ability. A sensitivity analysis revealed a 3-fold higher risk of CD in first-degree relatives of CD patients. Targeted testing of individuals with dermatitis herpetiformis, migraine, family history of CD, HLA DQ2/8 risk genotype, anaemia, type 1 diabetes, osteoporosis, or chronic liver disease could improve case-finding for CD, therefore expediting appropriate treatment and reducing adverse consequences. Migraine and chronic liver disease are not yet included as a risk factor in all CD guidelines, but it may be appropriate for these to be added. Future research should establish the diagnostic value of combining indicators.

Presents several experiments with heat and cold and discusses thermodynamics.

Inflammatory marker tests, such as C reactive protein, are simple, inexpensive, and commonly used in both primary and secondary care. 3 When we interviewed GPs about their use of inflammatory marker blood tests in primary care, all doctors mentioned potential harms as well as benefits of testing. 4 These could be divided into several categories; harms of the test itself, workload and financial costs, medicalisation of a patient's problem, patient anxiety, downstream costs, and harms of overdiagnosis. Overuse of diagnostic tests might reflect a societal culture of increasing risk aversion and rising medical litigation, as well as a culture in medicine that \"evinces a deep rooted unwillingness to acknowledge and embrace uncertainty.\" Tolerating uncertainty- the next medical revolution? N Engl J Med 2016; 358: 1713- 5. doi:10.1056/NEJMp1606402. pmid:27806221.

Although culture can be considered as a set of subjective values that oppose scientific objectivity, we challenge this view in this Commission by claiming that all people have systems of value that are unexamined. Such systems are, at times, diffuse, and often taken for granted, but are always dynamic and changing. They produce novel and sometimes perplexing needs, to which established caregiving practices often adjust slowly.

What you need to know Current UK guidelines for monitoring type 2 diabetes, chronic kidney disease, and hypertension are largely based on expert opinion; robust evidence for optimal monitoring strategies and testing intervals is lacking Unnecessary testing in primary care can lead to false positive and false negative results, increased workload for clinicians, and increased costs for the health service Patients and healthcare professionals should be aware of these uncertainties when making shared decisions about chronic disease monitoring Pathology tests have a unique place in management of chronic diseases. National Institute for Health and Care Excellence (NICE) Scottish Intercollegiate Guidelines Network (SIGN) Royal Colleges of Pathologists (RCPath), Physicians, and General Practitioners Quality Outcomes Framework (QOF) The following guidelines are included in this review: SIGN 116 Management of diabetes (2017)2 NICE CG127 Hypertension, the clinical management of primary hypertension in adults (2011)3 NICE CG182 Chronic kidney disease (partial update) (2014)4 NICE NG28 Type 2 diabetes in adults (2015)5 NICE PH38 Evidence reviews (Type 2 diabetes: prevention in people at high risk) (2017)6 RCPath: National minimum retesting intervals in pathology (2015)7 We extracted any guidance on the use of laboratory tests for disease monitoring, the recommended frequency of testing, and the level of evidence on which the guidance was based. [...]clinicians need to read an entire guideline to get an overview of all recommended tests. [...]SIGN recommends annual testing of renal function in patients with diabetes,2 whereas NICE suggest that test intervals should be determined by previous renal function results.4 NICE recommends that individual needs are taken into account when determining the frequency of monitoring, although it is not specified how testing intervals should be adjusted.5 “Blood glucose” should be tested routinely in patients with hypertension to screen for diabetes, according to NICE, but the frequency of such routine testing is not stated.3 Robust evidence for optimal monitoring strategies and testing intervals is lacking Most of these recommendations are based on expert opinion, provided by the respective guideline development groups.